Form 4: Integra LifeSciences: Executive Receives Stock Units

Robert T. Davis Jr., EVP & President of TR&DT at Integra LifeSciences, was granted 11,180 restricted stock units.

Summary

• Robert T. Davis Jr., Executive Vice President & President of TR&DT at Integra LifeSciences Holdings Corp., received a grant of 11,180 restricted stock units (RSUs).
• These RSUs were granted under the company's Fifth Amended and Restated 2003 Equity Incentive Plan.
• The RSUs will vest in full on the second anniversary of the grant date, July 1, 2026, provided Mr. Davis remains in continuous service with the company.
• Each RSU represents a contingent right to receive one share of Integra LifeSciences' common stock.
• The transaction was reported on July 6, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices rather than significant company performance news.

Positives

• Grant of restricted stock units to a key executive, indicating a commitment to retaining talent and aligning executive compensation with company performance.
• The grant of 11,180 RSUs suggests a belief in the future value of the company's stock.
• Vesting is tied to continued service, incentivizing long-term commitment from the executive.

Risks

• The vesting of RSUs is contingent on the Reporting Person's continued service, meaning any departure before the vesting date would result in forfeiture of the units.
• The value of the RSUs is subject to the fluctuation of Integra LifeSciences' common stock price.

Future Outlook

The vesting of the RSUs on July 1, 2026, is contingent on continued service, implying a positive outlook for the executive's tenure and the company's prospects through that date.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to senior executives are a common practice in the life sciences industry to attract, retain, and motivate key talent by aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with shareholders by providing equity-based compensation, potentially incentivizing long-term value creation.
• Employees: May signal stability in executive leadership within the TR&DT division.
• Management: Reinforces the company's compensation strategy for senior leadership.

Next Steps

• Vesting of 11,180 RSUs on July 1, 2026, subject to continued service.

Key Dates

Keywords

Integra LifeSciences, IART, Form 4, Restricted Stock Units, RSU Grant, Executive Compensation, Equity Incentive Plan, Robert T. Davis Jr.